Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Reports of Corrections and Removals, 19509-19510 [E8-7638]
Download as PDF
19509
Federal Register / Vol. 73, No. 70 / Thursday, April 10, 2008 / Notices
provisions. In response to this notice,
FDA received two general comments on
the information collection requirements
which are described in this document
along with FDA’s responses.
(Comment 1) The commenter
recommended that once a firm has
qualified for small business status, this
should be good enough for 3 to 5 years.
Further, that it would be quite unlikely
that a small business firm would move
from a small business to a huge business
in 3 years, particularly for the starting
business or very small business. The
commenter concluded that the extra
paperwork will cost time and money for
the industry and FDA as well.
(Response) FDA cannot accept this
recommendation, because current
provisions of the 2007 Amendments do
not permit the recommended approach.
Section 738(d)(2)(B) and (e)(2)(B) of the
act (21 U.S.C. 379j(d)(2)(B) and (e)(2)(B))
defines the ‘‘Evidence of Qualification’’
that must be provided to qualify as a
small business. The provisions
specifically require the applicant to
support its claim that it qualifies as a
small business by submitting, among
other things, the following:
• ‘‘a copy of the most recent Federal
income tax return for a taxable year’’
and
• A signed certification of gross
receipts or sales for the most recent
year.
Because both requirements specify
that the information must be for the
‘‘most recent’’ year, FDA cannot
determine whether an applicant’s status
as a small business will persist for a
period of more than 1 year.
(Comment 2) The commenter
expressed concern there could be some
problems in collecting the tax
certification information required of
Form FDA 3602A, Section III, from the
national taxing authority of each
country where an applicant has
business entities. The commenter cited
that in some countries, the national
taxing authority may not agree to fill out
this form for various reasons including:
(1) The fact that it may not be its own
official form, (2) the form is in English,
and (3) authorities do not agree to
determine the exchange rate for the U.S.
dollar.
As an alternative to Form FDA 3602A,
Section III, the commenter recommends
the following information be provided:
• A tax report or an income statement
from each country of business entities,
• Translation to English could be
organized by the applicant, and a
• Determination of exchange rate
could be done by the applicant.
(Response) FDA cannot accept this
recommendation because the agency
does not have authority to modify the
statutory requirement for a signed
certification form, and bearing the seal
of the national taxing authority of the
country in which the applicant, or if
applicable, affiliate, is headquartered
(see section 738(d)(2)(B)(iii) and
738(e)(2)(B)(iii)).
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
Form FDA 3602A
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
Sections I and II (completed by
the business seeking small
business status)
229
1
229
1
229
Section III (completed by the foreign national taxing authority)
33
7
231
1
231
Total
mstockstill on PROD1PC66 with NOTICES
1There
460
are no capital costs or operating and maintenance costs associated with this collection of information.
This burden estimate is based on an
examination of 510(k) premarket
notifications received during FY 2006
and FDA’s estimation of the time to
collect the required information to
complete Form FDA 3602A. The
evidence supporting each Form FDA
3602A must be reviewed by a foreign
national taxing authority to complete
Section III, the National Taxing
Authority Certification, of each Form
FDA 3602A. Because this is a new
activity, and neither FDA nor any
foreign national taxing authority has any
data that would provide an objective
measure of the effort required to
complete Section III, FDA is estimating
that the burden will be the same as FDA
experiences in reviewing Form FDA
3602, ‘‘FY 2008 MDUFMA Small
Business Qualification Certification For
a Business Headquartered in the United
States,’’ approved under OMB control
number 0910–0508.
FDA believes most entities that
submit Form FDA 3602A will not have
any affiliates, and very few will have
VerDate Aug<31>2005
16:48 Apr 09, 2008
Jkt 214001
more than three or four affiliates. Based
on our experience with FDA Form 3602,
FDA believes each business will require
1 hour to complete Sections I and II.
Because this is a new requirement, FDA
does not have any data on the time that
will be required to complete Section III,
the National Taxing Authority
Certification.
Dated: April 7, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–7637 Filed 4–9–08; 8:45 am]
Food and Drug Administration
[Docket No. FDA–2008–N–0213] (formerly
Docket No. 2007N–0460)
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Reports of
Corrections and Removals
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
BILLING CODE 4160–01–S
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 12,
2008.
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\10APN1.SGM
10APN1
19510
Federal Register / Vol. 73, No. 70 / Thursday, April 10, 2008 / Notices
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0359. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1472.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
SUPPLEMENTARY INFORMATION:
collection of information to OMB for
review and clearance.
Reports of Corrections and Removals—
21 CFR Part 806; (OMB Control Number
0910–0359)—Extension
The collection of information required
under the reports of corrections and
removals, part 806 (21 CFR part 806),
implements section 519(f) of the Federal
Food, Drug, and Cosmetic Act (the act)
(21 U.S.C. 360i(f)), as amended by the
Food and Drug Modernization Act of
1997 (FDAMA) (21 U.S.C. 301) (Public
Law 105–115). Each device
manufacturer or importer under
§ 806.10 shall submit a written report to
FDA of any action initiated to correct or
remove a device to reduce a risk to
health posed by the device, or to remedy
a violation of the act caused by the
device which may present a risk to
health, within 10 working days of
initiating such correction or removal.
Each device manufacturer or importer of
a device who initiates a correction or
removal of a device that is not required
to be reported to FDA under § 806.20
shall keep a record of such correction or
removal.
The information collected in the
reports of corrections and removals will
be used by FDA to identify marketed
devices that have serious problems and
to ensure that defective devices are
removed from the market. This will
assure that FDA has current and
complete information regarding these
corrections and removals and to
determine whether recall action is
adequate.
In the Federal Register of December
11, 2007 (72 FR 70327), FDA published
a 60-day notice requesting public
comment on the information collection
provisions. No comments were received.
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
806.10
Annual Frequency
per Response
488
Total Annual
Responses
1
Hours per
Response
488
Total Hours
10
Total
1There
4,880
4,880
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
21 CFR Section
806.20
Annual Frequency
per
Recordkeeping
132
Total Annual
Records
1
Hours per
Record
132
10
Total
mstockstill on PROD1PC66 with NOTICES
1There
Total Hours
1,320
1,320
are no capital costs or operating and maintenance costs associated with this collection of information.
In preparing the previous clearances
for approval of the information
collection requirements under §§ 806.10
and 806.20, FDA reviewed the reports of
corrections and removals submitted for
the previous 3 years under part 7 (21
CFR part 7), the agency’s recall
provisions. FDA has determined that
estimates of the reporting burden in
§ 806.10 should be revised to reflect a
1.2 percent increase for reports and
records submitted under part 7 due to
a decrease in class I and class II recall
actions. FDA also estimates the
reporting burden in § 806.20 should be
revised to reflect a reduction of 8
percent for reports and records
submitted under part 7 due to a
decrease in class III recall actions. The
time needed to collect information has
not been changed.
Dated: April 4, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–7638 Filed 4–9–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0202] (formerly
Docket No. 2008N–0009)
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Customer/Partner
Service Surveys
AGENCY:
Food and Drug Administration,
HHS.
VerDate Aug<31>2005
16:48 Apr 09, 2008
Jkt 214001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 12,
2008.
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0360. Also
include the FDA docket number found
ADDRESSES:
E:\FR\FM\10APN1.SGM
10APN1
Agencies
[Federal Register Volume 73, Number 70 (Thursday, April 10, 2008)]
[Notices]
[Pages 19509-19510]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-7638]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0213] (formerly Docket No. 2007N-0460)
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Reports of
Corrections and Removals
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by May 12,
2008.
[[Page 19510]]
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to baguilar@omb.eop.gov. All comments
should be identified with the OMB control number 0910-0359. Also
include the FDA docket number found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the
Chief Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1472.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Reports of Corrections and Removals--21 CFR Part 806; (OMB Control
Number 0910-0359)--Extension
The collection of information required under the reports of
corrections and removals, part 806 (21 CFR part 806), implements
section 519(f) of the Federal Food, Drug, and Cosmetic Act (the act)
(21 U.S.C. 360i(f)), as amended by the Food and Drug Modernization Act
of 1997 (FDAMA) (21 U.S.C. 301) (Public Law 105-115). Each device
manufacturer or importer under Sec. 806.10 shall submit a written
report to FDA of any action initiated to correct or remove a device to
reduce a risk to health posed by the device, or to remedy a violation
of the act caused by the device which may present a risk to health,
within 10 working days of initiating such correction or removal. Each
device manufacturer or importer of a device who initiates a correction
or removal of a device that is not required to be reported to FDA under
Sec. 806.20 shall keep a record of such correction or removal.
The information collected in the reports of corrections and
removals will be used by FDA to identify marketed devices that have
serious problems and to ensure that defective devices are removed from
the market. This will assure that FDA has current and complete
information regarding these corrections and removals and to determine
whether recall action is adequate.
In the Federal Register of December 11, 2007 (72 FR 70327), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
TABLE 1.--ESTIMATED ANNUAL REPORTING BURDEN\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
806.10 488 1 488 10 4,880
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 4,880
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2.--ESTIMATED ANNUAL RECORDKEEPING BURDEN\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual Frequency
21 CFR Section No. of per Total Annual Hours per Record Total Hours
Recordkeepers Recordkeeping Records
--------------------------------------------------------------------------------------------------------------------------------------------------------
806.20 132 1 132 10 1,320
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 1,320
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
In preparing the previous clearances for approval of the
information collection requirements under Sec. Sec. 806.10 and 806.20,
FDA reviewed the reports of corrections and removals submitted for the
previous 3 years under part 7 (21 CFR part 7), the agency's recall
provisions. FDA has determined that estimates of the reporting burden
in Sec. 806.10 should be revised to reflect a 1.2 percent increase for
reports and records submitted under part 7 due to a decrease in class I
and class II recall actions. FDA also estimates the reporting burden in
Sec. 806.20 should be revised to reflect a reduction of 8 percent for
reports and records submitted under part 7 due to a decrease in class
III recall actions. The time needed to collect information has not been
changed.
Dated: April 4, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-7638 Filed 4-9-08; 8:45 am]
BILLING CODE 4160-01-S